Rapid biosynthesis of glycoprotein therapeutics and vaccines from freeze-dried bacterial cell lysates.
Journal
Nature protocols
ISSN: 1750-2799
Titre abrégé: Nat Protoc
Pays: England
ID NLM: 101284307
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
11
03
2021
accepted:
22
11
2022
medline:
12
7
2023
pubmed:
17
6
2023
entrez:
16
6
2023
Statut:
ppublish
Résumé
The advent of distributed biomanufacturing platforms promises to increase agility in biologic production and expand access by reducing reliance on refrigerated supply chains. However, such platforms are not capable of robustly producing glycoproteins, which represent the majority of biologics approved or in development. To address this limitation, we developed cell-free technologies that enable rapid, modular production of glycoprotein therapeutics and vaccines from freeze-dried Escherichia coli cell lysates. Here, we describe a protocol for generation of cell-free lysates and freeze-dried reactions for on-demand synthesis of desired glycoproteins. The protocol includes construction and culture of the bacterial chassis strain, cell-free lysate production, assembly of freeze-dried reactions, cell-free glycoprotein synthesis, and glycoprotein characterization, all of which can be completed in one week or less. We anticipate that cell-free technologies, along with this comprehensive user manual, will help accelerate development and distribution of glycoprotein therapeutics and vaccines.
Identifiants
pubmed: 37328605
doi: 10.1038/s41596-022-00799-z
pii: 10.1038/s41596-022-00799-z
doi:
Substances chimiques
Glycoproteins
0
Vaccines
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2374-2398Subventions
Organisme : NCI NIH HHS
ID : F32 CA250324
Pays : United States
Informations de copyright
© 2023. Springer Nature Limited.
Références
US Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases 13th edn (eds Hamborsky, J., Korger, A. & Wolfe, C.) (Public Health Foundation, 2015).
FDA okays marketing of human insulin. Chem. Eng. News Arch. 60, 5 (1982).
Mullin, R. Cost to develop new pharmaceutical drug now exceeds $2.5 B. Scientific American https://www.scientificamerican.com/article/cost-to-develop-new-pharmaceutical-drug-now-exceeds-2-5b/ (24 November 2014).
Thiel, K. A. Biomanufacturing, from bust to boom…to bubble? Nat. Biotechnol. 22, 1365 (2004).
pubmed: 15529157
doi: 10.1038/nbt1104-1365
Jayapal, K. P., Wlaschin, K. F., Hu, W. & Yap, M. G. S. Recombinant protein therapeutics from CHO cells-20 years and counting. Chem. Eng. Prog. 103, 40 (2007).
Dolsten, M. & Sogaard, M. Precision medicine: an approach to R&D for delivering superior medicines to patients. Clin. Transl. Med. 1, 7 (2012).
pubmed: 23369459
pmcid: 3567426
doi: 10.1186/2001-1326-1-7
Ashok, A., Brison, M. & LeTallec, Y. Improving cold chain systems: challenges and solutions. Vaccine 35, 2217–2223 (2017).
pubmed: 27670076
doi: 10.1016/j.vaccine.2016.08.045
Kumru, O. S. et al. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies. Biologicals 42, 237–259 (2014).
pubmed: 24996452
doi: 10.1016/j.biologicals.2014.05.007
Choi, E. J. & Ling, G. S. Battlefield medicine: paradigm shift for pharmaceuticals manufacturing. PDA J. Pharm. Sci. Technol. 68, 312 (2014).
pubmed: 25035252
doi: 10.5731/pdajpst.2014.01002
Perez-Pinera, P. et al. Synthetic biology and microbioreactor platforms for programmable production of biologics at the point-of-care. Nat. Commun. 7, 12211 (2016).
pubmed: 27470089
pmcid: 4974573
doi: 10.1038/ncomms12211
Crowell, L. E. et al. On-demand manufacturing of clinical-quality biopharmaceuticals. Nat. Biotechnol. 36, 988–995 (2018).
Pardee, K. et al. Portable, on-demand biomolecular manufacturing. Cell 167, 248–259.e12 (2016).
pubmed: 27662092
doi: 10.1016/j.cell.2016.09.013
Salehi, A. S. et al. Cell-free protein synthesis of a cytotoxic cancer therapeutic: Onconase production and a just-add-water cell-free system. Biotechnol. J. 11, 274–281 (2016).
pubmed: 26380966
doi: 10.1002/biot.201500237
Adiga, R. et al. Point-of-care production of therapeutic proteins of good-manufacturing-practice quality. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-018-0259-1 (2018).
Adiga, R. et al. Manufacturing biological medicines on demand: Safety and efficacy of granulocyte colony-stimulating factor in a mouse model of total body irradiation. Biotechnol. Prog. 36, e2970 (2020).
pubmed: 31989790
doi: 10.1002/btpr.2970
Kightlinger, W., Warfel, K. F., DeLisa, M. P. & Jewett, M. C. Synthetic glycobiology: parts, systems, and applications. ACS Synth. Biol. 9, 1534–1562 (2020).
pubmed: 32526139
pmcid: 7372563
doi: 10.1021/acssynbio.0c00210
Sethuraman, N. & Stadheim, T. A. Challenges in therapeutic glycoprotein production. Curr. Opin. Biotechnol. 17, 341–346 (2006).
pubmed: 16828275
doi: 10.1016/j.copbio.2006.06.010
Sola, R. J. & Griebenow, K. Effects of glycosylation on the stability of protein pharmaceuticals. J. Pharm. Sci. 98, 1223–1245 (2009).
pubmed: 18661536
pmcid: 2649977
doi: 10.1002/jps.21504
Lin, C. W. et al. A common glycan structure on immunoglobulin G for enhancement of effector functions. Proc. Natl Acad. Sci. USA 112, 10611–10616 (2015).
pubmed: 26253764
pmcid: 4553773
doi: 10.1073/pnas.1513456112
Elliott, S. et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat. Biotechnol. 21, 414–421 (2003).
pubmed: 12612588
doi: 10.1038/nbt799
Jefferis, R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8, 226–234 (2009).
pubmed: 19247305
doi: 10.1038/nrd2804
Stark, J. C. et al. On-demand biomanufacturing of protective conjugate vaccines. Sci. Adv. 7, eabe9444 (2021).
pubmed: 33536221
pmcid: 7857678
doi: 10.1126/sciadv.abe9444
Jaroentomeechai, T. et al. Single-pot glycoprotein biosynthesis using a cell-free transcription-translation system enriched with glycosylation machinery. Nat. Commun. 9, 2686 (2018).
pubmed: 30002445
pmcid: 6043479
doi: 10.1038/s41467-018-05110-x
Hershewe, J. M. et al. Improving cell-free glycoprotein synthesis by characterizing and enriching native membrane vesicles. Nat. Commun. 12, 2363 (2021).
pubmed: 33888690
pmcid: 8062659
doi: 10.1038/s41467-021-22329-3
Schoborg, J. A. et al. A cell-free platform for rapid synthesis and testing of active oligosaccharyltransferases. Biotechnol. Bioeng. 115, 739–750 (2017).
pubmed: 29178580
doi: 10.1002/bit.26502
Jaroentomeechai, T. et al. A pipeline for studying and engineering single-subunit oligosaccharyltransferases. Methods Enzymol. 597, 55–81 (2017).
pubmed: 28935112
doi: 10.1016/bs.mie.2017.07.011
Kightlinger, W. et al. A cell-free biosynthesis platform for modular construction of protein glycosylation pathways. Nat. Commun. 10, 5404 (2019).
pubmed: 31776339
pmcid: 6881289
doi: 10.1038/s41467-019-12024-9
Lin, L. et al. Sequential glycosylation of proteins with substrate-specific N-glycosyltransferases. ACS Cent. Sci. 6, 144–154 (2020).
pubmed: 32123732
pmcid: 7047269
doi: 10.1021/acscentsci.9b00021
Natarajan, A. et al. Engineering orthogonal human O-linked glycoprotein biosynthesis in bacteria. Nat. Chem. Biol. 16, 1062–1070 (2020).
pubmed: 32719555
pmcid: 7857696
doi: 10.1038/s41589-020-0595-9
Warfel, K. F. et al. A low-cost, thermostable, cell-free protein synthesis platform for on demand production of conjugate vaccines. ACS Synth. Biol. 12, 95–107 (2023).
pubmed: 36548479
doi: 10.1021/acssynbio.2c00392
Silverman, A. D., Karim, A. S. & Jewett, M. C. Cell-free gene expression: an expanded repertoire of applications. Nat. Rev. Genet. 21, 151–170 (2020).
pubmed: 31780816
doi: 10.1038/s41576-019-0186-3
Perez, J. G., Stark, J. C. & Jewett, M. C. Cell-free synthetic biology: engineering beyond the cell. Cold Spring Harb. Perspect. Biol. 8, a023853 (2016).
pubmed: 27742731
pmcid: 5131772
doi: 10.1101/cshperspect.a023853
Hershewe, J., Kightlinger, W. & Jewett, M. C. Cell-free systems for accelerating glycoprotein expression and biomanufacturing. J. Ind. Microbiol. Biotechnol. 47, 977–991 (2020).
pubmed: 33090335
doi: 10.1007/s10295-020-02321-4
Williams, A. J. et al. A low-cost recombinant glycoconjugate vaccine confers immunogenicity and protection against enterotoxigenic Escherichia coli infections in mice. Preprint at bioRxiv https://doi.org/10.1101/2022.10.31.514630 (2022).
Tarui, H., Imanishi, S. & Hara, T. A novel cell-free translation/glycosylation system prepared from insect cells. J. Biosci. Bioeng. 90, 508–514 (2000).
pubmed: 16232900
doi: 10.1016/S1389-1723(01)80031-1
Moreno, S. N., Ip, H. S. & Cross, G. A. An mRNA-dependent in vitro translation system from Trypanosoma brucei. Mol. Biochem. Parasitol. 46, 265–274 (1991).
pubmed: 1922198
doi: 10.1016/0166-6851(91)90050-G
Shibutani, M., Kim, E., Lazarovici, P., Oshima, M. & Guroff, G. Preparation of a cell-free translation system from PC12 cell. Neurochem. Res. 21, 801–807 (1996).
pubmed: 8873084
doi: 10.1007/BF02532303
Mikami, S., Kobayashi, T., Yokoyama, S. & Imataka, H. A hybridoma-based in vitro translation system that efficiently synthesizes glycoproteins. J. Biotechnol. 127, 65–78 (2006).
pubmed: 16889861
doi: 10.1016/j.jbiotec.2006.06.018
Brodel, A. K. et al. IRES-mediated translation of membrane proteins and glycoproteins in eukaryotic cell-free systems. PLoS ONE 8, e82234 (2013).
pubmed: 24376523
pmcid: 3869664
doi: 10.1371/journal.pone.0082234
Gurramkonda, C. et al. Improving the recombinant human erythropoietin glycosylation using microsome supplementation in CHO cell-free system. Biotechnol. Bioeng. 115, 1253–1264 (2018).
pubmed: 29384203
doi: 10.1002/bit.26554
Lingappa, V. R., Lingappa, J. R., Prasad, R., Ebner, K. E. & Blobel, G. Coupled cell-free synthesis, segregation, and core glycosylation of a secretory protein. Proc. Natl Acad. Sci. USA 75, 2338–2342 (1978).
pubmed: 276877
pmcid: 392548
doi: 10.1073/pnas.75.5.2338
Rothblatt, J. A. & Meyer, D. I. Secretion in yeast: reconstitution of the translocation and glycosylation of alpha-factor and invertase in a homologous cell-free system. Cell 44, 619–628 (1986).
pubmed: 3512097
doi: 10.1016/0092-8674(86)90271-0
Valderrama-Rincon, J. D. et al. An engineered eukaryotic protein glycosylation pathway in Escherichia coli. Nat. Chem. Biol. 8, 434–436 (2012).
pubmed: 22446837
pmcid: 3449280
doi: 10.1038/nchembio.921
Feldman, M. F. et al. Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc. Natl Acad. Sci. USA 102, 3016–3021 (2005).
pubmed: 15703289
pmcid: 549450
doi: 10.1073/pnas.0500044102
Kightlinger, W. et al. Design of glycosylation sites by rapid synthesis and analysis of glycosyltransferases. Nat. Chem. Biol. 14, 627–635 (2018).
pubmed: 29736039
doi: 10.1038/s41589-018-0051-2
Ollis, A. A. et al. Substitute sweeteners: diverse bacterial oligosaccharyltransferases with unique N-glycosylation site preferences. Sci. Rep. 5, 15237 (2015).
pubmed: 26482295
pmcid: 4894442
doi: 10.1038/srep15237
Pan, C. et al. Biosynthesis of conjugate vaccines using an O-linked glycosylation system. MBio 7, e00443–16 (2016).
pubmed: 27118590
pmcid: 4850263
doi: 10.1128/mBio.00443-16
Harding, C. M. et al. A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host. Nat. Commun. 10, 891 (2019).
pubmed: 30792408
pmcid: 6385209
doi: 10.1038/s41467-019-08869-9
Kowarik, M. et al. Definition of the bacterial N-glycosylation site consensus sequence. EMBO J. 25, 1957–1966 (2006).
pubmed: 16619027
pmcid: 1456941
doi: 10.1038/sj.emboj.7601087
Li, M. et al. Shotgun scanning glycomutagenesis: a simple and efficient strategy for constructing and characterizing neoglycoproteins. Proc. Natl Acad. Sci. USA 118, e2107440118 (2021).
pubmed: 34551980
pmcid: 8488656
doi: 10.1073/pnas.2107440118
Kwon, Y. C. & Jewett, M. C. High-throughput preparation methods of crude extract for robust cell-free protein synthesis. Sci. Rep. 5, 8663 (2015).
pubmed: 25727242
pmcid: 4345344
doi: 10.1038/srep08663
Kim, D. M. & Swartz, J. R. Efficient production of a bioactive, multiple disulfide-bonded protein using modified extracts of Escherichia coli. Biotechnol. Bioeng. 85, 122–129 (2004).
pubmed: 14704994
doi: 10.1002/bit.10865
Cai, Q. et al. A simplified and robust protocol for immunoglobulin expression in Escherichia coli cell-free protein synthesis systems. Biotechnol. Prog. 31, 823–831 (2015).
pubmed: 25826247
pmcid: 5029582
doi: 10.1002/btpr.2082
Calhoun, K. A. & Swartz, J. R. An economical method for cell-free protein synthesis using glucose and nucleoside monophosphates. Biotechnol. Prog. 21, 1146–1153 (2005).
pubmed: 16080695
doi: 10.1021/bp050052y
Jewett, M. C. & Swartz, J. R. Mimicking the Escherichia coli cytoplasmic environment activates long-lived and efficient cell-free protein synthesis. Biotechnol. Bioeng. 86, 19–26 (2004).
pubmed: 15007837
doi: 10.1002/bit.20026
Cuccui, J. et al. Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis. Open Biol. 3, 130002 (2013).
pubmed: 23697804
pmcid: 3866875
doi: 10.1098/rsob.130002
Celik, E. et al. Glycoarrays with engineered phages displaying structurally diverse oligosaccharides enable high-throughput detection of glycan–protein interactions. Biotechnol. J. 10, 199–209 (2015).
pubmed: 25263089
doi: 10.1002/biot.201400354
Valvano, M. A. & Crosa, J. H. Molecular cloning and expression in Escherichia coli K-12 of chromosomal genes determining the O7 lipopolysaccharide antigen of a human invasive strain of E. coli O7:K1. Infect. Immun. 57, 937–943 (1989).
pubmed: 2645215
pmcid: 313202
doi: 10.1128/iai.57.3.937-943.1989
Ollis, A. A., Zhang, S., Fisher, A. C. & DeLisa, M. P. Engineered oligosaccharyltransferases with greatly relaxed acceptor-site specificity. Nat. Chem. Biol. 10, 816–822 (2014).
pubmed: 25129029
pmcid: 4575499
doi: 10.1038/nchembio.1609